<?xml version="1.0" encoding="UTF-8"?>
<p id="par0140">BSAAs could be combined with other antiviral agents to obtain synergistic or additive effects against certain viruses (
 <xref rid="bib0075" ref-type="bibr">Cheng et al., 2019</xref>, 
 <xref rid="bib0570" ref-type="bibr">Zheng et al., 2018</xref>). Several combination therapies which include BSAAs (such as abacavir/dolutegravir/lamivudine (Triumeq), darunavir/cobicistat/emtricitabine/tenofovir (Symtuza), lopinavir/ritonavir (Kaletra), ledipasvir/sofosbuvir and sofosbuvir/velpatasvir) became a standard for the treatment of HIV or HCV infections. Several synergistic drug combinations, such as obatoclax/saliphenylhalamide and gemcitabine/pimodivir, could enter clinical studies and become effective treatment of ZIKV and FLUAV infections (
 <xref rid="bib0150" ref-type="bibr">Fu et al., 2016</xref>, 
 <xref rid="bib0245" ref-type="bibr">Kuivanen et al., 2017</xref>).
</p>
